NVS.BA : Summary for NOVARTIS AG CEDEAR EACH REP 0.5 - Yahoo Finance

U.S. Markets closed

NOVARTIS AG CEDEAR EACH REP 0.5 (NVS.BA)


Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
577.000.00 (0.00%)
At close: 1:48PM ART
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close577.00
Open577.00
Bid583.25 x
Ask0.00 x
Day's Range577.00 - 577.00
52 Week Range566.85 - 585.00
Volume336
Avg. Volume17
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Market Realist7 hours ago

    Exploring Novartis’s 2016 Revenue

    Novartis (NVS) reported no change in its revenue on a constant currency basis in 2016 compared to 2015. The company's 2016 revenue fell to $48.5 billion.

  • Market Realist9 hours ago

    Novartis’s Valuation Compared to Its Peers’

    Novartis’s valuation has followed the industry’s overall trend over the last five years. Whether the healthcare sector’s valuation rises or falls, Novartis will definitely be affected.

  • Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
    Zacks2 days ago

    Novartis' Acute Heart Failure Drug Fails in Late-Stage Study

    Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).